Caremark Forecasts 25%-30% Mail Service Growth For 2001
Executive Summary
Caremark expects its mail order prescription volume to increase by 25%-30% during 2001, the company told a Nov. 1 earnings conference call.
You may also be interested in...
Medimmune Synagis DTC Ads Revamped To Target Mothers With Babies
Medimmune is retooling the direct-to-consumer ad campaign for its respiratory syncytial virus therapy Synagis (palivizumab), as the product enters its third RSV season on the market.
Medimmune Synagis DTC Ads Revamped To Target Mothers With Babies
Medimmune is retooling the direct-to-consumer ad campaign for its respiratory syncytial virus therapy Synagis (palivizumab), as the product enters its third RSV season on the market.
Xolair Advisory Committee Review Expected By Mid-2001, Tanox Says
Tanox is expecting an FDA advisory committee review for the Novartis/Genentech asthma treatment Xolair (omalizumab) during the first half of 2001.